Here are some key findings related to these targeted agents: (1) Inhibition of YES1: High‐throughput drug screening experiments in clear cell ovarian carcinoma revealed a synthetic lethal relationship between ARID1A mutations and the kinase inhibitor dasatinib, which targets YES1. Here, ARID1A is linked to ovarian clear cell cancer.